Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
MEDICAL TREATMENT IMPLEMENTATION AT 6-MONTHS FOLLOW-UP IN HOSPITALIZED AND AMBULATORY PATIENTS WITH HF ENROLLED IN THE BRING-UP3 HF STUDY
Anno:
2025
Background: Current ESC guidelines introduced a four-pillar approach for the treatment of HFrEF. Nevertheless, there is limited data regarding implementation, up-titration and discontinuation of recommended medical treatments in clinical practice. Objectives: BRING-UP-3 Heart Failure (HF) study was designed to evaluate the Guideline recommendations implementation in HF patients enrolled by…
Leggi di più
CARDIAC REVERSE REMODELING AFTER CARDIAC RESYNCHRONIZATION THERAPY
Anno:
2025
CLINICAL CASE PRESENTATION A 62-year-old female smoker went to the emergency room for ankle swelling. ECG showed sinus tachycardia, left bundle branch block (LBBB) and non-sustained ventricular tachycardias. Blood test revealed a mild elevation of high sensitivity cardiac troponin I (31 ng/L) and a remarkable elevation of amino-terminal pro-B-type natriuretic…
Leggi di più
Clinical advantage of the use of advanced algorithms for the management of heart failure in patients undergoing implantation of cardiac contractility modulation devices
Anno:
2025
INTRODUCTION. A 71-year-old man, with primary dilated cardiomyopathy with severe left ventricular dysfunction (LVDTD 60 mm, LVEF 20%), normal right ventricular function (RVDTD 36 mm, TAPSE 21 mm, RV S' TDI 11 cm/s) and moderate mitral regurgitation. In early 2019 he was hospitalized for heart failure and underwent implantation of…
Leggi di più
VERICIGUAT EFFECT ON RIGHT VENTRICULAR TO PULMONARY ARTERY COUPLING: A CASE REPORT
Anno:
2025
Introduction: In patients with pulmonary hypertension due to left heart disease (PH-LHD), optimizing treatment of the underlying condition is recommended. Vericiguat may be considered in patients who have had worsening heart failure (HF) even with guideline-directed medical therapy (GDMT), but despite its beneficial role on endothelial function, its effect…
Leggi di più
AGE- AND SEX-RELATED DIFFERENCES IN HEART FAILURE CHARACTERISTICS AND TREATMENT PATTERNS ACROSS THE EJECTION FRACTION SPECTRUM
Anno:
2025
Introduction: Older adults and females are under-represented in randomized clinical trials, and evidence on age – and sex-related differences in heart failure (HF) characteristics and treatment patterns is limited. Purpose: To evaluate differences in the clinical characteristics and treatments of an all-comers cohort of HF patients stratified by age…
Leggi di più
THE ROLE OF DAPAGLIFLOZIN IN MANAGING LEFT VENTRICULAR DYSFUNCTION IN DUCHENNE MUSCULAR DYSTROPHY PATIENTS
Anno:
2025
INTRODUCTION Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder associated with early and progressive degeneration of skeletal, smooth, and cardiac muscles, with progressive loss of ambulation, respiratory failure, and dilated cardiomyopathy. To date, there is limited data in the literature regarding the impact of different classes of cardioactive drugs…
Leggi di più
Clinical evaluation, symptomatology and hospitalization for patients with heart failure taken in charge in an out-of-hospital care pathway.
Anno:
2025
Background: Our aim was to assess the changes in patients diagnosed with HF in terms of quality of life, symptoms, hospital admissions and therapeutic adherence when taken in an extra-hospital therapeutic care path. Methods:  From January 23 to September 24, our cardiology clinic treated 192 patients diagnosed with heart failure. Among…
Leggi di più
CARDIAC RESYNCHRONIZATION THERAPY WITH BIVENTRICULAR PACING OR LEFT BUNDLE BRANCH PACING: A PROSPECTIVE REGISTRY
Anno:
2025
Background: Cardiac resynchronization therapy (CRT) with biventricular pacing (BiVP) is an established treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and wide QRS complexes, is effective in improving outcomes in patients who develop HF as a consequence of right ventricular pacing, and is indicated for patients with…
Leggi di più
EFFECT OF DAPAGLIFLOZIN ON LEFT VENTRICULAR REVERSE REMODELING IN MEDIUM AND SHORT-TERM, CORRELATED WITH BASAL FUNCTIONAL CAPACITY.
Anno:
2025
Aims: Dapagliflozin, a sodium-glucose cotransporter-2inhibitor (SGLT2) is approved for the treatment of heart failure (HF) regardless of ejection fraction. The aim of our study is to evaluate the effects of dapagliflozin in the medium and short-term on left ventricular reverse remodeling, correlating the possible improvement with the basal functional…
Leggi di più
EFFICACY OF VERICIGUAT IN A PATIENT WITH HFREF AND CLINICAL STABILITY, A CASE REPORT
Anno:
2025
Heart failure (HF) is a syndrome whit complex etiology associated with high mortality and hospitalization risk, despite therapeutic progress. Recent ESC (European Society of Cardiology) guidelines recommend vericiguat use in patients with reduced ejection fraction (HFrEF) with optimal medical therapy and recent episode of HF exacerbation (class IIb). Some…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram